Long-term follow-up of people treated with gene-modified T cell therapy
Follows people who received gene-modified T cell therapy in an earlier study for cancer.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Key facts
- Where
- Camperdown, Melbourne, and Murdoch, AustraliaSee the 4 sites
- Phase
- Phase 2/3
Where in Australia
- Royal Prince Alfred HospitalCamperdown, AustraliaTaking people
- Peter MacCallum Cancer CentreMelbourne, AustraliaTaking people
- The Alfred HospitalMelbourne, AustraliaTaking people
- Fiona Stanley HospitalMurdoch, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Celgene
- Trial code
- NCT03435796EU 2023-504201-36-00
- Record updated
- 2 November 2026
- Original description
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.Read full original descriptionShow less
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.
Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Inclusion: Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable; Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.
Exclusion: Not Applicable; Other protocol-defined inclusion/exclusion criteria apply.